CIK 0001621227 · Non-accelerated filer<br>Smaller reporting company
Adaptimmune Therapeutics PLC
Sign in to watch- Ticker
- ADAPY
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 44 1235 430000
- Business address
- 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE, United Kingdom
- Former names
- Adaptimmune Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 10 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-01 | Furey John Director | Grant or award · Option to purchase Ordinary Shares | +660,000 | 660,000 | ||
| 2024-07-01 | Alleva Lawrence M Director | Grant or award · Option to purchase Ordinary Shares | +1,213,926 | 1,213,926 | ||
| 2024-07-01 | Allen Andrew R Director | Grant or award · Option to purchase Ordinary Shares | +660,000 | 660,000 | ||
| 2024-07-01 | Behbahani Ali Director | Grant or award · Option to purchase Ordinary Shares | +1,144,686 | 1,144,686 | ||
| 2024-06-18 | Piccina Cintia Chief Commercial Officer | Sale | −24,531 | $0.93 | $23K | 38,293 |
| 2024-03-18 | Piccina Cintia Chief Commercial Officer | Grant or award · Option to purchase Ordinary Shares | +5,088,864 | 5,088,864 | ||
| 2024-03-18 | Piccina Cintia Chief Commercial Officer | Grant or award · Option to purchase Ordinary Shares | +1,130,832 | 1,130,832 | ||
| 2024-01-17 | Rawcliffe Adrian Chief Executive Officer | Sale | −30,080 | $0.67 | $20K | 44,848 |
| 2024-01-17 | Norry Elliot Chief Medical Officer | Sale | −5,309 | $0.67 | $4K | 7,785 |
| 2024-01-17 | Norry Elliot Chief Medical Officer | Sale | −12,967 | $0.67 | $9K | 19,257 |
| 2024-01-17 | Lunger John Chief Patient Supply Officer | Sale | −5,309 | $0.67 | $4K | 7,785 |
| 2024-01-17 | Lunger John Chief Patient Supply Officer | Sale | −12,805 | $0.67 | $9K | 19,015 |
| 2024-01-17 | Bertrand William C JR Chief Operating Officer | Sale | −5,309 | $0.67 | $4K | 7,785 |
| 2024-01-17 | Bertrand William C JR Chief Operating Officer | Sale | −13,599 | $0.67 | $9K | 20,201 |
| 2024-01-16 | Rawcliffe Adrian Chief Executive Officer | Sale | −9,304 | $0.79 | $7K | 14,104 |
| 2024-01-16 | Norry Elliot Chief Medical Officer | Sale | −2,287 | $0.79 | $2K | 3,363 |
| 2024-01-16 | Lunger John Chief Patient Supply Officer | Sale | −4,681 | $0.79 | $4K | 7,023 |
| 2024-01-16 | Bertrand William C JR Chief Operating Officer | Sale | −4,681 | $0.79 | $4K | 7,023 |
| 2024-01-15 | Behbahani Ali Director | Grant or award · Option to purchase Ordinary Shares | +40,950 | 40,950 | ||
| 2024-01-15 | Bertrand William C JR Chief Operating Officer | Grant or award · Option to purchase Ordinary Shares | +2,544,432 | 2,544,432 |
Page 3 of 23 · 454 trades